目的 分析哌拉西林他唑巴坦对支气管扩张患者肺功能、血沉（ESR）、C反应蛋白（CRP）水平的影响及疗效。方法 回顾性选取2015年7月-2017年8月马鞍山市中心医院收治的支气管扩张患者124例，根据治疗方法不同分为对照组和观察组。对照组患者采用常规治疗，观察组患者采用常规治疗联合哌拉西林他唑巴坦治疗，均连续治疗10 d。观察两组患者治疗前后发热、咳嗽咯痰、肺部湿啰音、肺部炎症缓解时间、痰液性质、肺功能指标、ESR、CRP水平变化情况。结果 观察组患者发热、咳嗽咯痰、肺部湿啰音、肺部炎症缓解时间均显著短于对照组，差异有统计学意义（P<0.05）。治疗前，两组患者痰液性质情况比较无统计学差异。治疗后，观察组患者黏液体积评分显著高于对照组，黏液密度、脓性黏液评分显著低于对照组，差异均有统计学意义（P<0.05）。治疗前，两组患者ESR、CRP水平比较无统计学差异。治疗后，观察组患者ESR、CRP水平均显著低于对照组（P<0.05）。治疗前，两组患者肺功能指标水平比较无统计学差异。治疗后，观察组患者FVC、FEV1水平均显著高于对照组（P<0.05）。结论 哌拉西林他唑巴坦治疗支气管扩张可改善患者痰液性质和肺功能，快速缓解临床症状，抑制患者ESR、CRP的表达。

Objective To analyze the effect and effect of piperacillin tazobactam on bronchiectasis, ESR, CRP level.Methods Review from July 2015 to August 2017 in our hospital 124 cases of patients with bronchiectasis, according to the different treatment methods were divided into control group and observation group. The control group was treated with conventional treatment, the observation group were treated by routine treatment combined with piperacillin tazobactam in the treatment, analysis of the clinical effect of two groups of patients after treatment.Results The observation group of patients with fever, cough, expectoration, pulmonary rales, lung inflammation remission time were shorter than the control group (P < 0.05). Before treatment, no significant differences between the two groups of patients with sputum properties. After treatment, the volume of patients observed mucus scores higher than the control group, the density of mucus, purulent mucus score below the control group (P < 0.05). The two groups of patients before treatment, ESR, CRP beta, no significant differences between the levels of CRP. After the treatment, the patients in the observation group were ESR, CRP water was lower than that of the control group (P < 0.05). Before treatment, there was no significant difference in the level of pulmonary function between the two groups. After treatment, the levels of FVC and FEV1 in the observation group were all higher than those in the control group (P < 0.05).Conclusion Piperacillin tazobactam in the treatment of bronchiectasis can improve the nature of sputum and lung function, quickly relieve the clinical symptoms, and inhibit the expression of ESR and CRP.